Abstract #1097

Amide proton transfer weighted signal of multiple sclerosis lesions and normal appearing white matter

Ibrahim Khormi^1,2,3, Oun Al-iedani^2,4, Stefano Casagranda⁵, Christos Papageorgakis⁵, Abdulaziz Alshehri^1,2,6, Rodney Lea², Patrick Liebig⁷, Saadallah Ramadan^1,2, and Jeannette Lechner-Scott^2,8,9

¹School of Health Sciences, University of Newcastle, Callaghan, Australia, ²Hunter Medical Research Institute, New Lambton Heights, Australia, ³College of Applied Medical Sciences, University of Jeddah, Jeddah, Saudi Arabia, ⁴School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, Australia, ⁵Department of R&D Advanced Applications, Olea Medical, La Ciotat, France, ⁶Department of Radiology, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal University, Al Khobar, Saudi Arabia, ⁷Siemens Healthineers, Erlangen, Germany, ⁸School of Medicine and Public Health, University of Newcastle, New Lambton Heights, Australia, ⁹Department of Neurology, John Hunter Hospital, New Lambton Heights, Australia

Synopsis

Keywords: CEST / APT / NOE, Multiple Sclerosis

Motivation: Monitoring disease progression in people with relapsing-remitting multiple sclerosis (pw-RRMS) presents a substantial clinical challenge. Conventional MRI often fails to provide molecular biomarkers for pathophysiological changes like myelin protein accumulation indicative of demyelination.

Goal(s): The study aimed to validate whether amide proton transfer weighted (APTw) imaging could be a sensitive molecular marker for detecting demyelination in MS lesions.

Approach: We conducted APTw imaging at 3T on 24 pw-RRMS, evaluating the signal intensity within MS lesions compared to contralateral normal-appearing white matter (cNAWM) regions.

Results: The investigation revealed a statistically significant increase in APTw signal intensity in MS lesions compared to cNAWM regions.

Impact: Elevated APTw signal intensity could serve as a non-invasive molecular biomarker for demyelination, potentially aiding in the more accurate monitoring of MS disease progression and treatment efficacy.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.